Literature DB >> 27177200

Post-PEGylation of siRNA Lipo-oligoamino Amide Polyplexes Using Tetra-glutamylated Folic Acid as Ligand for Receptor-Targeted Delivery.

Katharina Müller1, Eva Kessel1,2, Philipp M Klein1, Miriam Höhn1, Ernst Wagner1,2.   

Abstract

For efficient and receptor-specific siRNA delivery, a new post-PEGylation strategy was established to provide siRNA polyplexes with targeting and shielding agents. For this purpose, core nanoparticles were formed by complexing siRNA with sequence-defined cationic lipo-oligomers. The T-shaped bis-oleoyl-oligoethanamino amides 454 and 595, containing stabilizing tyrosine and cysteine residues, were applied. These core nanoparticles were surface-shielded by reaction with maleimido-polyethylene glycol (Mal-PEG) reagents, optionally containing the targeting ligand folic acid (FolA). The PEGylation had two unpredicted consequences. First, FolA-PEG surface-modified polyplexes agglomerated due to the hydrophobicity of folic acid, resulting in ligand-independent gene silencing. This problem was solved by the use of tetra-γ-glutamyl folic acid (gE4-FolA) as targeting ligand. Post-PEGylated gE4-FolA siRNA polyplexes displayed sizes of 100-200 nm and mediated receptor specific uptake and effective gene silencing. Second, PEGylation triggered a destabilization of polyplexes, which was uncritical in cell culture but a limiting factor in vivo, as revealed by biodistribution studies in mice. This problem was partially overcome by selecting 595 (containing two CRC stability motifs) for polyplex core formation and an optimized lower degree of gE4-FolA PEGylation reagent. Biodistribution in L1210 tumor bearing mice demonstrated a significantly reduced lung signal and extended persistence of siRNA polyplexes (up to 8 h), with moderate delivery into the tumor. Further polyplex stabilization will be required for effective tumor-targeted delivery.

Entities:  

Keywords:  folic acid; polyglutamylation; post-PEGylation; sequence defined oligomers; siRNA; targeting ligand

Mesh:

Substances:

Year:  2016        PMID: 27177200     DOI: 10.1021/acs.molpharmaceut.6b00102

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  4 in total

Review 1.  Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.

Authors:  Byungji Kim; Ji-Ho Park; Michael J Sailor
Journal:  Adv Mater       Date:  2019-09-30       Impact factor: 30.849

2.  Folic acid modified TPGS as a novel nano-micelle for delivery of nitidine chloride to improve apoptosis induction in Huh7 human hepatocellular carcinoma.

Authors:  Danni Li; Shaogang Liu; Jiahao Zhu; Liqun Shen; Qi Ying Zhang; Hua Zhu
Journal:  BMC Pharmacol Toxicol       Date:  2021-01-06       Impact factor: 2.483

3.  Overcoming the non-kinetic activity of EGFR1 using multi-functionalized mesoporous silica nanocarrier for in vitro delivery of siRNA.

Authors:  Javad Parnian; Leila Ma'mani; Mohamad Reza Bakhtiari; Maliheh Safavi
Journal:  Sci Rep       Date:  2022-10-14       Impact factor: 4.996

Review 4.  Solid-phase supported design of carriers for therapeutic nucleic acid delivery.

Authors:  Ana Krhac Levacic; Stephan Morys; Ernst Wagner
Journal:  Biosci Rep       Date:  2017-10-31       Impact factor: 3.840

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.